Oncolysate-loaded Escherichia coli bacterial ghosts enhance the stimulatory capacity of human dendritic cells

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2017-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00262-016-1932-4PMID 27864613PMCID PMC11029152
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice

  2016cited by this paper
• [Dendritic cell-based therapeutic cancer vaccines].

  2016cited by this paper
• Lentivirus-induced ‘Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma

  2015cited by this paper
• Development of a potent melanoma vaccine capable of stimulating CD8+ T-cells independently of dendritic cells in a mouse model

  2015cited by this paper
• Decreased HIV-Specific T-Regulatory Responses Are Associated with Effective DC-Vaccine Induced Immunity

  2015cited by this paper
• Melanoma cell lysate induces CCR7 expression and in vivo migration to draining lymph nodes of therapeutic human dendritic cells

  2014cited by this paper
• Direct Type I IFN but Not MDA5/TLR3 Activation of Dendritic Cells Is Required for Maturation and Metabolic Shift to Glycolysis after Poly IC Stimulation

  2014cited by this paper
• Optimizing Dendritic Cell-Based Approaches for Cancer Immunotherapy

  2014cited by this paper
• Vibrio cholerae ghosts (VCG) exert immunomodulatory effect on dendritic cells for enhanced antigen presentation and induction of protective immunity

  2014cited by this paper
• Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised “proof-of-principle” phase II study

  2014cited by this paper
• Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs.

  2014cited by this paper
• Therapeutic cancer vaccines and combination immunotherapies involving vaccination

  2014cited by this paper
• Cellular and molecular mechanisms in cancer immune escape: a comprehensive review

  2014cited by this paper
• Dendritic cells matured in the presence of TLR ligands overcome the immunosuppressive functions of regulatory T cells

  2014cited by this paper
• Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines.

  2014cited by this paper
• Clinical use of dendritic cells for cancer therapy.

  2014cited by this paper
• Chemoimmunotherapy: reengineering tumor immunity

  2013cited by this paper
• Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells.

  2013cited by this paper
• Dendritic Cells in Cancer Immunotherapy Clinical Trials: Are We Making Progress?

  2013cited by this paper
• Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.

  2013cited by this paper
• Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.

  2013cited by this paper
• Therapeutic dendritic cell-based cancer vaccines: the state of the art.

  2013influential reference
• A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside

  2013cited by this paper
• Dendritic-cell-based therapeutic cancer vaccines.

  2013cited by this paper
• Inhibition of CD4+CD25+ Regulatory T Cell Function and Conversion into Th1-Like Effectors by a Toll-Like Receptor-Activated Dendritic Cell Vaccine

  2013cited by this paper
• Dendritic Cells in the Cancer Microenvironment

  2012cited by this paper
• Regulation of Immune Responses by Prostaglandin E2

  2012cited by this paper
• Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications

  2012cited by this paper
• Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy

  2012cited by this paper
• Combining immunotherapy and targeted therapies in cancer treatment

  2012cited by this paper
• IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing.

  2012cited by this paper
• Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™

  2011cited by this paper
• Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles

  2011cited by this paper
• Cytotoxic immunotherapy strategies for cancer: Mechanisms and clinical development

  2011cited by this paper
• Targeting mutations predictably.

  2011cited by this paper
• The bacterial ghost platform system

  2010cited by this paper
• Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• IFN-alpha in the generation of dendritic cells for cancer immunotherapy.

  2009cited by this paper
• Effective gene transfer to melanoma cells using bacterial ghosts.

  2008cited by this paper
• DNA-loaded bacterial ghosts efficiently mediate reporter gene transfer and expression in macrophages.

  2005cited by this paper
• Bacterial Ghosts as Novel Efficient Targeting Vehicles for DNA Delivery to the Human Monocyte-Derived Dendritic Cells

  2005cited by this paper
• alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity.

  2004cited by this paper
• Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli

  2004influential reference
• Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes

  2004cited by this paper
• Bacterial Ghosts Are an Efficient Delivery System for DNA Vaccines1

  2004cited by this paper
• Activation of Lysosomal Function During Dendritic Cell Maturation

  2003cited by this paper
• Conditioned medium from HeLa cells enhances motility of human monocyte-derived dendritic cells but abrogates their maturation and endocytic activity.

  2001cited by this paper
• Tumor-Specific CD4+ T Lymphocytes from Cancer Patients Are Required for Optimal Induction of Cytotoxic T Cells Against the Autologous Tumor

  2000cited by this paper
• Cross-Priming of Naive Cd8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells

  2000cited by this paper
• Pro‐inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum‐free conditions

  1997cited by this paper

• Bacterial ghosts (BGs): A promising approach as candidate vaccine

  2026cites this paper
• Engineered Streptococcus suis Bacterial Ghosts via Lytic Plasmid and Cell-Penetrating Peptides for Enhanced Protective Immunity.

  2025cites this paper
• Engineered bacteria/bacterial components strategy for glioma

  2025cites this paper
• Klebsiella pneumoniae ghosts as a novel adjuvant drive dendritic cell maturation and antigen-specific TCM expansion for IFN-γ-mediated immune protection

  2025cites this paper
• Genetically Engineered Bacterial Ghosts as Vaccine Candidates Against Klebsiella pneumoniae Infection

  2025cites this paper
• Topical drug delivery strategies for enhancing drug effectiveness by skin barriers, drug delivery systems and individualized dosing

  2024cites this paper
• Novel strategies for modulating the gut microbiome for cancer therapy.

  2024cites this paper
• Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature

  2024cites this paper
• Bacterial and bacterial derivatives-based drug delivery systems: a novel approach for treating central nervous system disorders

  2024cites this paper
• Effects of intratumoral microbiota on tumorigenesis, anti-tumor immunity, and microbe-based cancer therapy

  2024cites this paper
• A Simple and Rapid Method of Probiotic Bacterial Ghost Cell Preparation to Deliver Mycobacterium tuberculosis Antigen

  2024cites this paper
• Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies

  2023cites this paper
• Advances in immunomodulatory strategies for host-directed therapies in combating tuberculosis.

  2023cites this paper
• Biomimetic and bioinspired nano‐platforms for cancer vaccine development

  2023cites this paper
• Engineered Living Materials for Advanced Diseases Therapy

  2023cites this paper
• Bacterial extracellular vesicles: Emerging nanoplatforms for biomedical applications.

  2023cites this paper
• Cancer cell membrane-coated bacterial ghosts for highly efficient paclitaxel delivery against metastatic lung cancer

  2023cites this paper
• Bacteria and Bacterial Components as Natural Bio-Nanocarriers for Drug and Gene Delivery Systems in Cancer Therapy

  2023cites this paper
• Extracellular nanovesicles produced by Bacillus licheniformis: A potential anticancer agent for breast and lung cancer.

  2023cites this paper
• Bacterial membrane vesicles for vaccine applications.

  2022cites this paper
• Bacterial extracellular vesicles-based therapeutic strategies for bone and soft tissue tumors therapy

  2022cites this paper
• Advances of bacteria-based delivery systems for modulating tumor microenvironment.

  2022cites this paper
• Pathological features-based targeted delivery strategies in IBD therapy: A mini review.

  2022cites this paper
• E. coli Membrane Vesicles as a Catalase Carrier for Long-Term Tumor Hypoxia Relief to Enhance Radiotherapy.

  2021cites this paper
• Bacterial Ghosts-Based Vaccine and Drug Delivery Systems

  2021cites this paper
• The development of ghost vaccines trials

  2020cites this paper
• Bacteria-Inspired Nanomedicine.

  2020cites this paper
• Subcutaneous Immunization of Dogs With Bordetella bronchiseptica Bacterial Ghost Vaccine

  2019cites this paper
• Harnessing the Immunomodulatory Properties of Bacterial Ghosts to Boost the Anti-mycobacterial Protective Immunity

  2019cites this paper
• Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis

  2018cites this paper
• Bioengineered cellular and cell membrane‐derived vehicles for actively targeted drug delivery: So near and yet so far

  2018cites this paper
• Tumor lysate-loaded Bacterial Ghosts as a tool for optimized production of therapeutic dendritic cell-based cancer vaccines.

  2018cites this paper